SOPHIA ANTIPOLIS, France – January 30, 2025 │ Roche’s new $570M near‑term licensing deal for MediLink’s YL201 underscores the strategic premium placed on differentiated ADC assets—and on the IP required to defend them. Roche announced an exclusive licensing agreement with China’s MediLink Therapeutics for YL201, an investigational antibody–drug conjugate (ADC) targeting B7-H3 (CD276). Roche will[…]
SOPHIA ANTIPOLIS, France – November 21, 2025 │ October 21, 2025 – Takeda has entered into a license and collaboration agreement with Innovent Biologics for the development, manufacturing and commercialization of two late-stage oncology medicines, worldwide outside of Greater China. First, there is IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, evaluated in non-small cell lung[…]
SOPHIA ANTIPOLIS, France – October 24, 2025 │ Hansoh Pharmaceutical has signed a license agreement with Roche to develop HS-20110, a CDH17-targeting antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor payload. Hansoh Pharma gives Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to advance the clinical development and[…]
SOPHIA ANTIPOLIS, France – July 10, 2025 │ In July, Regeneron received accelerated approval from the FDA for its bispecific antibody (bsAb) Linvoseltamab (brand name Lynozyfic). It is intended to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least 4 prior lines of therapy, including a proteasome inhibitor,[…]